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ABSTRACT
Objective. To examine the success of stabi-
lisation and the short term outcomes from 
the routine use of nasal high flow (nHF) on 
an unselected cohort of babies in the deliv-
ery room (DR).
Design. Retrospective single-centre study
Setting. Single-centre neonatal intensive 
care unit (NICU)
Patients. Infants born at < 32 weeks gesta-
tion
Interventions. Stabilisation and transfer to 
NICU of an unselected cohort of babies us-
ing nHF
Main outcome measures. Success of sta-
bilisation defined by successful transfer 
on nHF and clinical measures of stability 
at admission to NICU, including oxygen 
requirement, admission temperature, sur-
factant requirement, short term outcomes 
and whether infants were sustained on 
nHF by 72 hours of age. 
Results. There were 133 eligible babies. 
54 were commenced on nHF in the DR 
(Group A), 47 were stabilised by face 
mask CPAP (continuous positive airway 
pressure) (Group B), 26 were intubated 
(Group C); 6 required only minimal res-
piratory support (Group D). Median ma-
turity varied between the groups (Group 
A 27+5 weeks, Group B 30 weeks, Group 
C 26+2 weeks, Group D 31+5). 72% of 
Group A and 75% of Group B remained 
on nHF for 72 hours (P=0.82). Fewer ba-
bies received surfactant in Group A versus 
Group B (29% vs 35%; P=0.67), however 
groups were not matched for maturity dif-
ferences and Group A were significantly 
less mature and of lower birthweight (both 
P<0.001). Group A were significantly more 
likely to be in air at admission than Group 
B (P=0.03).
Conclusion. Preterm babies can be suc-
cessfully stabilised and sustained on nHF. 
The use of nHF for immediate stabilisation 
appears to be effective and, in this study, 
led to significantly more babies being in 
air on admission to the NICU compared to 
face mask CPAP stabilisation.  
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INTRODUCTION
The majority of babies born prematurely 
require stabilisation, not resuscitation, in 
the Delivery Room (DR). Whilst the latest 
guidance supports the use of nasal Con-
tinuous Positive Airway Pressure (CPAP), 
(1,2)  with evidence of improved outcomes 
compared with routine invasive respirato-
ry support, (3,4) we recently demonstrated 
the feasibility of the use of nasal high flow 
(nHF) in the stabilisation of premature 
babies (23 to 29+6 weeks gestation) in the 
delivery room prior to transfer to Neonatal 
Intensive Care Unit (NICU). (5)
Although several large studies have previ-
ously demonstrated that nHF is generally 
as effective as nCPAP for postextubation 
support, (6-8) there remains a paucity of 
literature on the use of nHF in the DR. 
Our previous study showed that stabilisa-
tion on nHF reduced the rate of DR intu-
bation and surfactant administration com-
pared to our prior practice. However our 
work was biased due to the requirement 
for consent to be obtained prior to deliv-
ery, which probably selected a “healthier” 
population of babies due to the time availa-
ble for antenatal preparation with steroids, 
magnesium and interventions for optimal 
maternal health and delivery. It is thus 
arguably more relevant to monitor inter-
ventions in a “real-world” setting. Here we 
present data on a subsequent unselected 
cohort of preterm babies who underwent 




This was a retrospective observational 
study to examine the short term outcomes 
from the routine use of nHF to stabilise an 
unselected cohort of babies born before 32 
weeks gestation in the DR. We also wanted 
to see whether there were differences be-
tween using nHF and face mask CPAP for 
stabilisation, and results were compared 
using Fisher’s exact test and Student’s t-test 
as appropriate.
Setting
We collected data for babies born between 
23 and 31+6 weeks at St Peter’s Hospital, 
Chertsey, Surrey, UK between April 2015 
and October 2016. We recorded the in-
fant’s gestational age, birthweight, whether 
babies required nHF, nCPAP or intubation 
in the DR, admission FiO2 and tempera-
ture, need for surfactant and inotropes. We 
gathered information about pneumotho-
rax, pulmonary haemorrhage, severe IVH 
(Intraventricular haemorrhage) (grade III-
IV) and whether nHF was sustained for 72 
hours. Stabilisation of babies using nHF 
is our routine practice, therefore parental 
consent was not sought.
We used the same mobile nHF apparatus 
we previously built (figure 1). This device 
can be taken to each delivery and takes 
about 5 minutes to reach 37°C. We fol-
lowed the same clinical protocol for stabi-
lisation as we did in our pilot study (figure 
2). 
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RESULTS
Participants
A total of 133 eligible babies were admitted 
to NICU during the study period. Mean 
birth weight was 1080g (median 1014, 
mode 1100, range 340-2140, CI 1014-1145, 
SD 383) and mean gestational age 28+2 
weeks (median 28+1, mode 27+2, range 
23+1-31+6, CI 28+0-28+5, SD 2+1).
Outcomes
Group A consisted of babies commenced 
on nHF in the DR. Group B consisted of 
babies stabilised using face mask CPAP in 
the DR. Group C were babies who required 
intubation and Group D were babies who 
required minimal or no additional stabi-
lisation. Results are presented as median 
values.
Th ere were 54 (41%) babies with median 
gestation 27+5 weeks and birthweight 
935g in Group A. Group B consisted of 
48 (36%) babies with median gestation 
of 30+0 weeks and birthweight 1267g. 
Group C contained 25 infants (19%), 
ranging from 23+1 to 30+4 weeks gesta-
tion (median 26+2) and birthweight 730g 
(range 340-1537g). Group D consisted of 
6 babies with a median gestational age of 
31+5 weeks and median birthweight 1695g 
(range 1340-2140g).
In Group A, the median admission tem-
perature was 36.8°C and FiO2 on admis-
sion was 0.25, with a mode value of 0.21 in 
22 (43%) of the 51 babies in whom this was 
recorded. 16 (29%) needed surfactant and 
15 (28%) required intubation (12 (80%) of 
those were given surfactant), and 4 (7%) 
babies received inotropes during the fi rst 
72 hours. 39 (72%) were sustained on nHF 
during the fi rst 72 hours, 4 (10%) of them 
required surfactant given by LISA (Less 
Invasive Surfactant Administration) pro-
cedure, and 4 (7%) received inotropes. Th e 
4 babies requiring surfactant but sustained 
on nHF had a median gestation of 27+2 
weeks (CI 24+0-29+4) and birth weight of 
758g (CI 423-1185), and one of these had a 
Grade III/IV IVH, but no other complica-
tion was noted. 3 (6%) babies in Group A 
had IVH Grade III/IV and no baby had a 
pulmonary haemorrhage. Two (4%) babies 
developed pneumothoraces. Th e least ma-
ture baby in Group A was 24+1 weeks ges-
tation and remained on nHF by 72 hours 
of age. 
In Group B (n=47) the median admis-
sion temperature was 36.9°C, and FiO2 
on admission was 0.3. Ten (22%) of those 
recorded (n=45) were in air on admission 
to NICU. Babies were started on nHF on 
admission to NICU as per routine practice. 
17 (36%) required surfactant. 36 (77%) 
remained on HF for at least 72 hours, 8 
(22%) of those received surfactant by the 
LISA procedure. Th e 8 babies requiring 
surfactant but sustained on nHF had a 
median gestation of 29+5 weeks (CI 27+0-
30+5) and birth weight of 1157g (CI 946-
1361). Th e smallest baby was 24+3 weeks 
gestation with birth weight 780g. 12 ba-
bies (26%) required intubation, 9 of those 
(75%) received surfactant. 1 (2%) baby 
developed a pneumothorax and received 
inotropes. Th ere were no babies with pul-
monary haemorrhage or IVH grade III/IV. 
In Group C (n=26) the median admis-
sion temperature was 36.9°C (range 36°C 
– 38.3°C; CI 36.6-37.2;), with FiO2 on ad-
mission 0.3 (n= 17; range 21% - 100%; CI 
0.23-0.49) with 7 (27%) babies in room air. 
5 (19%) received inotropes, 2 (8%) babies 
developed a pneumothorax, 2 (8%) babies 
had Grade III or IV IVH and 1 (4%) baby 
suff ered a pulmonary haemorrhage. 24 
(92%) babies received surfactant, 3 (12%) 
were extubated on to HF on the unit and 
sustained on HF by 72 hours of life, all of 
them receiving surfactant before extuba-
tion. 
Two (1.5%) babies required facial oxygen 
only in the DR, 1 of them was subsequent-
ly intubated on the unit. Four babies (3%) 
were breathing in air unsupported. None of 
these babies required surfactant, inotropic 
support or had pneumothorax, pulmonary 
haemorrhage, IVH grade III/IV.
Table 1 shows the analysis of Groups A and 
B. Th ere were signifi cant diff erences be-
tween the groups in the Gestational Ages 
and Birthweights, with Group B containing 
more mature and heavier babies. Babies in 
Group A were signifi cantly more likely to 
be in room air by the time of admission to 
NICU (P=0.03).
DISCUSSION
In our previous pilot study (5) we showed 
that 60% of preterm babies could be sus-
tained on nHF for at least the fi rst 72 
hours. In this work we demonstrated that 
72% of babies who received nHF in the DR 
were sustained on nHF for 72 hours, so 
there has been an apparent improvement 
despite the population being unselected, 
although this might simply be due to 
small study numbers. Our antenatal ster-
oid administration rates are still approxi-
mately 90%, which probably accounts for 
the relatively good respiratory status of the 
preterm babies in the study.
In this study, we show that signifi cantly 
more babies were in room air by the time 
of admission to NICU if stabilised on nHF, 
rather than facemask CPAP. Th is implies a 
high level of clinical stability, which is in 
line with our experiences. However there 
are no diff erences between Groups A and 
B between the stabilisation modes in terms 
of sustained non-invasive ventilation.
Th e stabilisation of babies using non-in-
vasive techniques also reduces surfactant 
use compared to historical practices. Our 
data also shows that 43% of all babies <32 
weeks required surfactant. Th is compares 
favourably with our previous study where 
48% of babies were given surfactant. In this 
Figure 1. Th e mobile nHF unit
Figure 2. Protocol for use of nasal High 
Flow in babies <32 weeks gestation
CPAP, continuous positive airway pres-
sure; nHF, nasal High Flow ; NICU, neo-
natal intensive care unit.  
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study, 30% of babies received surfactant 
in Group A compared to 36% in Group 
B. This was not a significant difference 
but did not account for the significant dif-
ferences in maturity and weight between 
the 2 groups. Since group B was, on aver-
age, 11 days more mature and 315 grams 
heavier at birth, this may mask important 
differences in sustained nHF success and 
surfactant use, and a controlled study is 
required to investigate that. Unsurpris-
ingly the smallest and least mature babies 
required intubation in the DR. Almost all 
of the babies intubated required surfactant 
administration (92%).
The rates of complications are comparable 
with previous stabilisation studies using 
nCPAP. We fully acknowledge the limita-
tions of this work, which is a retrospective 
evaluation in a single centre with con-
siderable expertise in managing preterm 
babies on nHF, and with excellent back-
ground rates of antenatal steroid use. 
However we believe that the stability at 
admission of the majority of babies, the 
significant numbers of babies in air by 
the time of admission to NICU, the high 
proportions sustained on nHF for at least 
72 hours, and the trend towards lower 
surfactant use should be encouraging for 
clinical teams who wish to consider alter-
native stabilisation strategies. We specu-
late that the use of nHF may reduce the 
need for oxygen due to the positive effects 
of inhaling warmed, humidified gas in re-
ducing work of breathing compared to the 
cold dry gas used for face mask stabilisa-
tion.
CONCLUSION
We have shown that, under non-study con-
ditions, it is feasible to stabilise and sustain 
babies using nHF in the DR. This practice 
led, in this study, to significantly more ba-
bies being in air by the time of admission, 
and reduced surfactant use compared to 
our historical practice. Our work was per-
formed in a single centre with considerable 
experience in the use of nHF in babies, us-
ing a single device (Vapotherm Precision 
Flow) and our experiences and results can-
not be automatically extrapolated to other 
situations or devices. However nHF in the 
DR appears to offer effective stabilisation 
for the majority of premature babies and 
remains our standard practice.
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